Chronic Pain News and Research

RSS

Injecting PAP may reduce chronic pain: Research

A study published in the Aug. 4, 2010 issue of the Journal of Neuroscience introduces an enzyme that could pack a big punch in the battle against chronic pain. Its name is prostatic acid phosphatase or PAP for short. According to researchers at the University of North Carolina at Chapel Hill, PAP blocks pain in animal models by siphoning off a molecule called PIP2—a critical component of the chemical cascade behind chronic pain.

5 Aug 2010

Arthritis treatment costs more than $128 billion a year in the U.S.

Arthritis is the single greatest cause of chronic pain and disability among Americans and the treatment of arthritis costs the nation more than $128 billion a year in medical care and lost earnings. Persistent, chronic joint pain determines the choices people make and limits their ability to perform basic tasks for themselves and their family. Eighty percent of Americans either have, or know someone who has, arthritis and these numbers continue to escalate.

4 Aug 2010

$International study of more than 60,000 women highlights additional risk associated with fractures$

International study of more than 60,000 women highlights additional risk associated with fractures

Researchers seeking to understand the impact of osteoporosis and fractures on various aspects of health have found that women who had previous fractures experienced a significant reduction in health-related quality of life similar to or worse than that experienced by patients with diabetes, arthritis, lung disease and other chronic illnesses. This latest study from the Global Longitudinal Study of Osteoporosis in Women (GLOW), which is based at the Center for Outcomes Research at the University of Massachusetts Medical School, was published online.

3 Aug 2010

Intrinsic brain connectivity in fibromyalgia associated with chronic pain intensity

A recent study from researchers at Massachusetts General Hospital and University of Michigan provides the first direct evidence of linkage between elevated intrinsic (resting-state) brain connectivity and spontaneous pain intensity in patients with fibromyalgia (FM). This research shows an interaction of multiple brain networks, offering greater understanding of how pain arises. Details of the study appear online and in the August issue of Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology.

30 Jul 2010

FDA approves two SCS leads for use with Boston Scientific's Precision Plus Spinal Cord Stimulator System

Boston Scientific Corporation today announced U.S. Food and Drug Administration approval of two spinal cord stimulation (SCS) leads for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk and/or limbs. The Linear™ 3-4 and Linear™ 3-6 Percutaneous Leads offer wider contact spacing to expand the lead choices available to physicians. The Company plans to launch the products immediately in the U.S.; they were launched in Europe and other international markets earlier.

30 Jul 2010

Resting brain activity associated with spontaneous fibromyalgia pain

29 Jul 2010

Cipher Pharmaceuticals second-quarter net revenues increase to $2.2 million

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three and six months ended June 30, 2010.

28 Jul 2010

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.

28 Jul 2010

Millennium Laboratories urges for increase in physician reimbursement for POC urine drug screening

Millennium Laboratories, Inc., a national, research-based medication monitoring company specifically focused on clinicians who treat chronic pain, strongly advocated for an increase in physician reimbursement for point-of-care urine drug screening at the Annual Clinical Laboratory Public Meeting of the Centers for Medicare and Medicaid Services on July 22, 2010.

27 Jul 2010

Diagnostic guidelines for arthritis-related back pain result in excessive tests, delay in pain relief: Research

Slavishly following long-held guidelines for diagnosing the cause of arthritis-related back pain is resulting in excessive tests, delays in pain relief and wasteful spending of as much as $10,000 per patient, new Johns Hopkins-led research suggests.

26 Jul 2010

New drug to treat chronic pain in SCD patients

A University of Minnesota Medical School research team led by Kalpna Gupta, Ph.D., has discovered that cannibinoids offer a novel approach to ease the chronic and acute pain caused by sickle cell disease.Using a mouse model of SCD, Gupta and University of Minnesota colleagues studied the pain mechanisms by observing animals that exhibited both musculoskeletal pain and temperature sensitivity, symptoms similarly experienced by humans with SCD. The team compared two classifications of drugs in their ability to manage pain sensed by the animals, the traditionally prescribed classification of drugs, opioids, with a new therapeutic approach, cannabinoids, a synthetic compound based on marijuana derivatives. Currently, the only approved treatment for management of severe pain in SCD is opioids.

23 Jul 2010

Arcion reports top-line results from ARC-4558 Phase 2b clinical trial for painful diabetic neuropathy

Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, today announced top-line results from a successful Phase 2b double-blind, randomized, placebo-controlled clinical trial of its lead topical pain candidate, ARC-4558, in adult patients with painful diabetic neuropathy (PDN). Arcion recently held an End of Phase 2 meeting with the United States Food and Drug Administration (FDA) and the ARC-4558 program is now poised to enter Phase 3 studies.

20 Jul 2010

Obesity, chronic pain linked to family history, mood disorders: Study

Though it is well known obese individuals have a high incidence of persistent pain problems, a new study in The Journal of Pain, published by the American Pain Society, reports that comorbid obesity and pain also are linked to family history and mood disorders.

20 Jul 2010

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

A Phase 3 open-label study, recently published online by Pain Practice, has compared tapentadol extended release tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release tablets.

20 Jul 2010

Diamyd Medical receives US Federal Trade Commission's antitrust clearance

Diamyd Medical AB has received antitrust clearance that closes the transaction announced on June 22, 2010 with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a Johnson & Johnson company.

16 Jul 2010

Columbia scientists discover new way to alleviate chronic pain

Columbia scientists working to combat injury-related depression, substance abuse and suicide due to unremitting, persistent pain may have discovered a new way of treating that pain: a powerful analgesic dubbed N60 that leads to neither tolerance nor addiction.

16 Jul 2010

Zogenix secures $35M financing for commercial launch of SUMAVEL DosePro needle-free delivery system

Zogenix, Inc., a privately held pharmaceutical company, announced that it has secured a $35 million debt facility led by Oxford Finance Corporation which also included Silicon Valley Bank. The facility consists of a $25 million term loan and a $10 million revolving line of credit. Concurrently, all existing Zogenix investors, including Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, Abingworth Management, and Chicago Growth Partners, have provided an additional $15 million investment.

14 Jul 2010

Reducing chronic pain, dry mouth could improve quality of life in head and neck cancer patients: Study

Head and neck cancer patients who reported poor sleep quality one year after diagnosis had more symptoms of chronic pain and complaints of dry mouth related to radiation treatments, according to a recent study from the University of Michigan Comprehensive Cancer Center.

12 Jul 2010

Student-led team awarded top honor in 2010 CIMIT Prize in Primary Healthcare competition

Imagine finding out before you leave the pediatrician's office if your child has strep throat, or even something more serious requiring a different treatment. A novel application for applying DNA "nanobarcodes" in a clinical assay could help primary-care physicians quickly and more accurately determine what's causing a patient's acute pharyngitis from an easy throat swab.

9 Jul 2010

FDA approves Purdue's Butrans Transdermal System CIII for management of chronic pain

Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved Butrans™ (buprenorphine) Transdermal System CIII for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Butrans Transdermal System is an analgesic product that delivers continuous release of medication for seven days.

2 Jul 2010

Chronic Pain News and Research

Injecting PAP may reduce chronic pain: Research

Arthritis treatment costs more than $128 billion a year in the U.S.

International study of more than 60,000 women highlights additional risk associated with fractures

Intrinsic brain connectivity in fibromyalgia associated with chronic pain intensity

FDA approves two SCS leads for use with Boston Scientific's Precision Plus Spinal Cord Stimulator System

Resting brain activity associated with spontaneous fibromyalgia pain

Cipher Pharmaceuticals second-quarter net revenues increase to $2.2 million

Regeneron second-quarter total revenues increase to $115.9 million

Millennium Laboratories urges for increase in physician reimbursement for POC urine drug screening

Diagnostic guidelines for arthritis-related back pain result in excessive tests, delay in pain relief: Research

New drug to treat chronic pain in SCD patients

Arcion reports top-line results from ARC-4558 Phase 2b clinical trial for painful diabetic neuropathy

Obesity, chronic pain linked to family history, mood disorders: Study

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

Diamyd Medical receives US Federal Trade Commission's antitrust clearance

Columbia scientists discover new way to alleviate chronic pain

Zogenix secures $35M financing for commercial launch of SUMAVEL DosePro needle-free delivery system

Reducing chronic pain, dry mouth could improve quality of life in head and neck cancer patients: Study

Student-led team awarded top honor in 2010 CIMIT Prize in Primary Healthcare competition

FDA approves Purdue's Butrans Transdermal System CIII for management of chronic pain

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News